A physiologically relevant in vitro model gut system
Lead Research Organisation:
Newcastle University
Department Name: Inst for Cell and Molecular Biosciences
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
People |
ORCID iD |
| Jeff Pearson (Principal Investigator) |
| Description | The market need for integrated in vitro model of digestion and absorption was established. Freedom to operate and competitive landscaper were assessed. |
| Exploitation Route | The market insight and competitive landscape helped develop a business model for a spin out company using this technology developed in BB/G00563X/1. |
| Sectors | Agriculture, Food and Drink,Healthcare,Pharmaceuticals and Medical Biotechnology |
| URL | https://aeliusbiotech.co.uk/ |
| Description | The project is was ongoing until 29 Mar 2015. The findings so far have been used to build a case of support for the patent filed by Newcastle University (GB1320781.6) from technology developed in BB/G00563X/1. The project produced market understanding which led to the application and award of the BBSRC Follow on Fund. Title: An integrated upper GI model of digestion and absorption - the commercial 'Holy Grail'. This award led to the development of the in vitro small intestinal model. This is now available to other researchers and industry through the university. It is being looked into as potentially forming the basis of a new spin-out from Newcastle University. This technology is now being offered commercially through our spin out company Aelius Biotech. The company already has generated over £200,000 in business since late 2017. |
| First Year Of Impact | 2009 |
| Sector | Agriculture, Food and Drink,Chemicals,Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology |
| Impact Types | Economic |
| Description | An integrated upper GI model of digestion and absorption - the commercial 'Holy Grail' |
| Amount | £152,719 (GBP) |
| Funding ID | BB/N012666/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2016 |
| End | 09/2017 |
| Description | ICURE Set-Squared |
| Amount | £35,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2015 |
| End | 04/2016 |
| Title | Integrated small intestinal model |
| Description | The pathfinder award allowed us to understand the market need for an absorptive gastrointestinal model. With this we applied for follow on funding, and developed the first cell culture model capable of integrating a mucus barrier and digestive fluids. |
| Type Of Material | Model of mechanisms or symptoms - in vitro |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | The developed model has been used in commercial projects to assist drug development with Boehringer Ingelheim, Oxford Pharmascience and Suntory |
| Title | Model Gut System |
| Description | The system mimics the chemical and enzymatic digestion taking place in the upper digestive tract of a human, from the mouth to the end of the small intestine. |
| Type Of Material | Model of mechanisms or symptoms - in vitro |
| Year Produced | 2013 |
| Provided To Others? | Yes |
| Impact | This tool was used to screen numerous bioactive compounds and correctly predict the outcomes of the clinical trial based on them. |
| URL | http://www.ncl.ac.uk/business/commercialisation/transfer/biomedical-sciences/mgs.htm |
| Company Name | AELIUS BIOTECH LIMITED |
| Description | Aelius Biotech specialise in lab models of the aerodigestive tract. Our predictive systems can help you understand your formulation during vital pre-clinical stages to help you improve and de-risk product development and get successful products to market. |
| Year Established | 2018 |
| Impact | Data from the MGS showed that alginate is released in the small intestinal phase- the major site of lipase activity and significantly reduced fat digestion. The in vitro data built a solid evidence base for subsequent in vivo human studies. After a successful acceptability study a pilot human proof of principle study then went on to demonstrate that alginate bread can reduce the level of circulating triglycerides in plasma after a meal as well as significantly increase the level of fat in ileal effluent. Jon Farrimond. Scientific and Regulatory Affairs Suntory Beverage and Food (Europe) - "We have worked with Aelius Biotech on the development of two products that have gone to human trials to support EFSA health claims and have seen the value that reliable in vitro models can provide. The model has helped us make numerous key decision and investments. I am sure these models will be used by industry to accelerate and improve product development." |
| Website | https://aeliusbiotech.co.uk/ |